142155-44-0

Basic information

• Product Name: CIZOLIRTINE CITRATE,ETHANAMINE, N,N-DIMETHYL-2-[(1-METHYL-1H-PYRAZOL-5-YL)PHENYLMETHOXY]-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE
• Synonyms: CIZOLIRTINE CITRATE,ETHANAMINE, N,N-DIMETHYL-2-[(1-METHYL-1H-PYRAZOL-5-YL)PHENYLMETHOXY]-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE;E 4018
• CAS NO: 142155-44-0
• Molecular Formula: C15H21N3O.C6H8O7
• Molecular Weight: 451.473
• Mol File: 142155-44-0.mol

Chemical Properties

• Boiling Point: 366°Cat760mmHg
• Flash Point: 175.2°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 1.51E-05mmHg at 25°C
• CAS DataBase Reference: CIZOLIRTINE CITRATE,ETHANAMINE, N,N-DIMETHYL-2-[(1-METHYL-1H-PYRAZOL-5-YL)PHENYLMETHOXY]-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: CIZOLIRTINE CITRATE,ETHANAMINE, N,N-DIMETHYL-2-[(1-METHYL-1H-PYRAZOL-5-YL)PHENYLMETHOXY]-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(142155-44-0)
• EPA Substance Registry System: CIZOLIRTINE CITRATE,ETHANAMINE, N,N-DIMETHYL-2-[(1-METHYL-1H-PYRAZOL-5-YL)PHENYLMETHOXY]-, 2-HYDROXY-1,2,3-PROPANETRICARBOXYLATE(142155-44-0)

Safety Data

• Hazardous Substances Data: 142155-44-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C15H21N3O.C6H8O7/c1-17(2)11-12-19-15(13-7-5-4-6-8-13)14-9-10-16-18(14)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-10,15H,11-12H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)

Upstream product

• 77-92-9 citric acid 
• 142155-43-9 2-[phenyl(1-methyl-1H-pyrazol-5-yl)methoxy]-N,N-dimethylethanamine 

Relevant articles and documents

1-METHYLPYRAZOLE MODULATORS OF SUBSTANCE P, CALCITONIN GENE-RELATED PEPTIDE, ADRENERGIC RECEPTOR, AND/OR 5-HT RECEPTOR

The present invention relates to new 1-methylpyrazole modulators of substance P release, calcitonin gene-related peptide activity, adrenergic receptor activity, and/or 5 -HT receptor activity, pharmaceutical compositions thereof, and methods of use thereof.

Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence

Derivatives of aryl(or heteroaryl)azolylcarbinols of general formula (I), in which Ar represents a phenyl radical or a thienyl radical, optionally substituted, R1 represents a hydrogen atom or a lower alkyl group, R2 represents a dialkylaminoalkyl or azaheterocylclylalkyl and Het represents an azole unsubstituted or optionally substituted by one or two substituents, and their physiologically acceptable salts; are useful as drugs in human and/or veterinary therapeutics to treat urinary incontinence in mammals, including man.

Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of troubles mediated by an excess of substance P

The present invention relates to the use of derivatives of aryl (or heteroaryl) azolylcarbinols of general formula (1) of the specification, as well as their physiologically acceptable salts, in the manufacture of medicaments, useful in human and/or veterinary therapy, for the treatment of disorders that are mediated by an excess of substance P, and especially disorders of the central nervous system such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders.

UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION

The derivatives of aryl(or heteroaryl)azolylcarbinol (I), in which R1 is an atom of hydrogen or a lower alkyl group; R2 is a dialkylaminoalkyl or azaheterocyclylalkyl radical; Ar is a phenyl or thienyl radical, optionally substituted; and Het is a heterocyclic five-membered azotic aromatic ring that contains from one to three nitrogen atoms, optionally substituted, are suitable for the treatment of neurogenic inflammation, present in different processes, such as diabetes, asthma, cystitis, gingivitis, migraine, dermatitis, rhinitis, psoriasis, inflammation of sciatic and lumbar nerves, gastrointestinal processes, ocular inflammation, etc., in mammals, including man.